PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 106 filers reported holding PMV PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,221,761 | -3.6% | 4,596,378 | -1.7% | 0.00% | 0.0% |
| Q2 2023 | $29,278,195 | +52.3% | 4,677,028 | +16.1% | 0.00% | 0.0% |
| Q1 2023 | $19,223,905 | -36.0% | 4,030,169 | +16.8% | 0.00% | 0.0% |
| Q4 2022 | $30,026,894 | -24.9% | 3,451,367 | +2.7% | 0.00% | 0.0% |
| Q3 2022 | $39,987,000 | -16.4% | 3,360,323 | +0.1% | 0.00% | -50.0% |
| Q2 2022 | $47,854,000 | -12.9% | 3,358,144 | +27.2% | 0.00% | +100.0% |
| Q1 2022 | $54,970,000 | -6.3% | 2,640,350 | +4.0% | 0.00% | 0.0% |
| Q4 2021 | $58,670,000 | -10.0% | 2,539,824 | +16.1% | 0.00% | -50.0% |
| Q3 2021 | $65,199,000 | -0.5% | 2,187,923 | +14.1% | 0.00% | 0.0% |
| Q2 2021 | $65,525,000 | +39.7% | 1,918,134 | +34.5% | 0.00% | +100.0% |
| Q1 2021 | $46,897,000 | -43.3% | 1,425,873 | +6.0% | 0.00% | -66.7% |
| Q4 2020 | $82,731,000 | +330.0% | 1,345,015 | +148.1% | 0.00% | +200.0% |
| Q3 2020 | $19,242,000 | – | 542,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |